Sarepta Therapeutics CEO Doug Ingram to Step Down by End of 2026 Amid Controversial Tenure

Sarepta Therapeutics CEO Douglas Ingram announced plans to step down by the end of 2026 or upon appointment of a successor, after nearly 9 years leading the company.1 2 3 4 6

Ingram cited family commitments, including recent diagnoses of myotonic dystrophy type 1 (DM1) in two immediate family members, as the reason for his 'deeply difficult' decision.2 3 4

The announcement followed a tumultuous 2025 for Sarepta, marked by two patient deaths linked to its gene therapy Elevidys, FDA investigation, voluntary shipment halt, 500 job cuts, and halted development of other therapies.1 2 3

Sarepta's Q4 2025 revenue was $442.9 million (beat expectations), but the company reported a wider-than-expected adjusted loss per share of $3.58; full-year net product revenue was $1.86 billion.3

The company has begun a comprehensive search for Ingram's replacement, considering internal and external candidates, and described 2026 as a 'critical reset year' for Elevidys amid safety concerns and physician hesitation.1 2 3 4

SRPT shares slid nearly 4% in after-hours trading following the earnings report and CEO news.3